Copenhagen, 2015-08-05 16:33 CEST (GLOBE NEWSWIRE) -- Copenhagen, 5 August 2015 – Zealand informs that the company has received a major shareholder announcement from Kapitalforeningen LD (KLD), an investment fund wholly-owned by Lønmodtagernes Dyrtidsfond (LD), Dirch Passers Allé 27, 2nd Floor, 2000 Frederiksberg, Denmark (corporate registration no. 61 55 28 12).
Pursuant to Section 29 of the Danish Securities Act, cf. Executive order no. 668 of 25 June 2012 on major shareholders and the Danish Companies Act, section 55, cf. section 56, KLD has informed Zealand that the fund after sale of shares now holds nominally DKK 2,351,707 shares in Zealand Pharma A/S, corresponding to 9.99 % of the company’s share capital and voting rights.
KLD has been shareholder in Zealand since before the company’s IPO in November 2010.
●●●●●
For further information, please contact:
Hanne Leth Hillman, Senior Vice President for Investor Relations and Communications
Tel: +45 50 60 36 89, email: hlh@zealandpharma.com
About Zealand Pharma
Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) is a biotechnology company with world leading expertise in the identification, design and development of novel peptide-based medicines, with competences spanning also in-house clinical trial design and management. The company is advancing a proprietary pipeline of novel medicines alongside a portfolio of products and development projects under license collaborations - and with a therapeutic focus in the fields of metabolic diseases and acute care indications.
Zealand’s first invented medicine, lixisenatide, is a once-daily prandial GLP-1 agonist for the treatment of Type 2 diabetes, which is marketed globally (ex-US) as Lyxumia® under a license agreement with Sanofi. The agreement, covers also LixiLan, a new fixed-ratio combination of lixisenatide and insulin glargine (Lantus®) in Phase III development. Lixisenatide was submitted for regulatory approval in the US in late July 2015, and regulatory submissions of LixiLan are planned for Q4 2015 in the US and Q1 2016 in the EU.
The proprietary pipeline include danegaptide (prevention of Ischemic Reperfusion Injury) in Phase II and the stable glucagon analogue, ZP4207 in two clinical programs; as a single-use rescue pen (severe hypoglycemia) in preparation for Phase II and a multiple-dose version (mild to moderate hypoglycemia) in Phase I as well as several preclinical peptide therapeutics.
Zealand currently has global license agreements and collaborations with Sanofi, Helsinn Healthcare and Boehringer Ingelheim.
Zealand is based in Copenhagen, Denmark. For further information: www.zealandpharma.com and follow us on Twitter @ZealandPharma.
